Skip to main content
SpringerLink
Log in

Entecavir monotherapy cost effective for CHB in China

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. 2014 US dollars

Reference

  • Lai K, et al. Cost-Effectiveness Comparison Between the Response-Guided Therapies and Monotherapies of Nucleos(t)ide Analogues for Chronic Hepatitis B Patients in China. Clinical Drug Investigation : 7 Dec 2016. Available from: URL: http://doi.org/10.1007/s40261-016-0486-8

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Entecavir monotherapy cost effective for CHB in China. PharmacoEcon Outcomes News 769, 12 (2017). https://doi.org/10.1007/s40274-017-3648-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-017-3648-x

Search

Navigation